Skip to content

A study of the efficacy and safety about neoadjuvant chemoradiotherapy combined with planned surgery for cervical esophageal squamous cell carcinoma

A study of the efficacy and safety about neoadjuvant chemoradiotherapy combined with planned surgery for cervical esophageal squamous cell carcinoma

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019633
Enrollment
Unknown
Registered
2018-11-20
Start date
2018-12-01
Completion date
Unknown
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical esophageal cancer

Interventions

Case series:Planned surgery after concurrent chemoradiotherapy.

Sponsors

Shandong ENT Hospital Affiliated to Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Cervical esophageal squamous cell carcinoma confirmed by pathology; 2. The lesion is suitable for concurrent chemoradiotherapy and potentially resectable; 3. The patients could provide biopsy,fresh tumor tissue or pleuroperitoneal fluids samples; 4. Without distant metastasis; 5. Without making radical head and neck surgery; 6. Life expectancy = 6 months, age 18-75 years old and ECOG 0-1; 7. Without obvious abnormalities of ECG; 8. Without obvious abnormalities of blood routine, liver function and renal function affectting concurrent chemoradiotherapy and surgery; 9. Have not received any chemotherapy and radiation therapy and endocrine therapy; 10. The patient voluntarily signed the informed consent form, with good compliance, willing active treatment and follow-up.

Exclusion criteria

Exclusion criteria: 1. Planned surgery cannot be performed after radiotherapy and chemotherapy; 2. The patient was confirmed to living with other cancers which may cause interferences to this resaerch; 3. Cannot quit tobacco and alcohol during treatment; 4. Pregnant and lactating women; 5. With active gastrointestinal bleeding; 6. Combined with other serious diseases, such as myocardial infarction within 6 months, malignant hypertension, chronic pancreatitis, hepatitis B antigen positive, etc; 7. Participate in other clinical trials within or four weeks.

Design outcomes

Primary

MeasureTime frame
PFS;OS;Local control rate;

Countries

China

Contacts

Public ContactWei Xu

Shandong ENT Hospital Affiliated to Shandong University

xuwhns@126.com+86 053168777578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026